Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece.

Machine translation Machine translation
类别 Primary study
期刊Alimentary pharmacology & therapeutics
Year 2006
連結 Pubmed, DOI
目的：为了确定长期应对干扰素治疗乙肝患者e抗原阴性的慢性乙肝和因素进行反应和生存独立相关。 方法：60例患者与α-干扰素治​​疗一年记录在案乙肝e抗原阴性的慢性乙型肝炎患者，随访期为6年。 结果：持续生化和病毒学反应被认为在34.91％的患者在6 33.33％和随访，分别和组织学的改善在持续应答的54.5％12个月的非应答者（7.1％，P = 0.004相比，卡方检验），在6个月的随访。多因素分析表明，在6个月的治疗乙肝病毒DNA水平的患者<10,000拷贝/毫升有复发的可能性很低，与那些有水平相比> 10 000拷贝/ mL（P = 0.032）。年龄（> 65岁）和乙肝病毒DNA水平在治疗6个月（> 10,000拷贝/毫升）为疾病进展和生存的独立因素（P = 0.041和P = 0.044分别）。6年来，持续的反应仍然存在于患者19.04％，其中4.8％已经开发抗-HBs。 结论：通过定量聚合酶链反应在6个月的治疗乙型肝炎病毒DNA的监测可以允许早期响应于干扰素-α的预测，并且可以用作疾病进展的在未来的一个指标。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 66a8bfcb01b80d30fa26114d2578a30ce2048bcb
First added on: Mar 10, 2015
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use